Molecular abnormalities of the p53 pathway in dedifferentiated liposarcoma

被引:0
作者
Tos, APD
Doglioni, C
Piccinin, S
Maestro, R
Mentzel, T
Barbareschi, M
Boiocchi, M
Fletcher, CDM
机构
[1] TREVISO REG HOSP, DEPT PATHOL, BELLUNO, ITALY
[2] TREVISO REG HOSP, DEPT PATHOL, Trento, ITALY
[3] CRO, DEPT EXPT ONCOL 1, AVIANO, ITALY
[4] INST PATHOL, JENA, GERMANY
[5] HARVARD UNIV, BRIGHAM & WOMENS HOSP, SCH MED, DEPT PATHOL, BOSTON, MA 02115 USA
关键词
liposarcoma; dedifferentiated liposarcoma; dedifferentiation; cell cycle regulators; p53; mdm2;
D O I
10.1002/(SICI)1096-9896(199701)181:1<8::AID-PATH700>3.0.CO;2-#
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Dedifferentiated liposarcoma represents a distinct subtype of liposarcoma and is characterized by the presence of abrupt transition from well-differentiated liposarcoma to high-grade pleomorphic sarcoma (mostly MFH-like). A key role for p53 in tumour progression of this subset of liposarcomas has been suggested on the basis of p53 immunopositivity, A series of 14 dedifferentiated liposarcomas has been investigated by analysing the p53 gene and protein together with the p53-related molecules p21(Waf1) and mdm2, to verify whether the p53 pathway is involved in the development and progression of this tumour type, The results indicate that the p53 gene is rarely involved in dedifferentiated liposarcoma (7 per cent of cases analysed) and that low percentages of p53 immunopositivity are still compatible with integrity of the p53 gene. This concept is also supported by the observed preservation of p21(Waf1) immunoreactivity in all but the p53-mutated cases. By contrast, mdm2 overexpression emerges as the most frequent abnormality in dedifferentiated liposarcoma (57 and 78 per cent of cases in well-dedifferentiated and high-grade areas, respectively).
引用
收藏
页码:8 / 13
页数:6
相关论文
共 31 条
[1]  
ANDREASSEN A, 1993, CANCER RES, V53, P468
[2]  
CORDONCARDO C, 1994, CANCER RES, V54, P794
[3]   CYTOGENETIC AND FLUORESCENCE IN-SITU HYBRIDIZATION INVESTIGATION OF RING CHROMOSOMES CHARACTERIZING A SPECIFIC PATHOLOGICAL SUBGROUP OF ADIPOSE-TISSUE TUMORS [J].
DALCIN, P ;
KOOLS, P ;
SCIOT, R ;
DEWEVER, I ;
VANDAMME, B ;
VANDEVEN, W ;
VANDENBERGHE, H .
CANCER GENETICS AND CYTOGENETICS, 1993, 68 (02) :85-90
[4]  
Dei Tos Angelo P., 1994, American Journal of Surgical Pathology, V18, P913, DOI 10.1097/00000478-199409000-00006
[5]  
Doglioni C, 1996, J PATHOL, V179, P248, DOI 10.1002/(SICI)1096-9896(199607)179:3<248::AID-PATH571>3.0.CO
[6]  
2-6
[7]   THE P53 TUMOR-SUPPRESSOR GENE AND TUMOR PROGNOSIS - IS THERE A RELATIONSHIP [J].
DOWELL, SP ;
HALL, PA .
JOURNAL OF PATHOLOGY, 1995, 177 (03) :221-224
[9]  
Fletcher CDM, 1996, AM J PATHOL, V148, P623
[10]  
FLETCHER CDM, 1995, AM J SURG PATHOL, V19, P1216